Article ID Journal Published Year Pages File Type
5702724 Urologic Oncology: Seminars and Original Investigations 2017 6 Pages PDF
Abstract
A longer time to reach a PSA nadir after treatment with AA, but not Enz, appeared to be associated with favorable disease control in patients with docetaxel-naïve mCRPC.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide
Authors
, , , , , , , , , , ,